Faricimab

CAT: 0804-HY-P99116-01Size: 1 mgDry Ice: YesHazardous: No
CAT#:0804-HY-P99116-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) . Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951) . Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) [1][2][3][4][5].
CAS Number
[1607793-29-2]
Product Name Alternative
RG7716; RO-6867461
UNSPSC
12352203
Target
VEGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/faricimab.html
Purity
97.97
Solubility
H2O
Smiles
[Faricimab]
Molecular Weight
(146.16 kDa)
References & Citations
[1]Sahni J, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 Aug;126 (8) :1155-1170.|[2]Nicolò M, et al. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases[J]. Expert Opin Investig Drugs. 2021 Mar;30 (3) :193-200. |[3]Penha FM, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME[J]. Int J Retina Vitreous. 2024 Jan 17;10 (1) :5.|[4]Canonica J, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion[J]. Front Cell Neurosci. 2023 Jun 12;17:1192464.|[5]Jørstad ØK, et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties[J]. Int J Retina Vitreous. 2023 Nov 7;9 (1) :65.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched

Alternative Products

CatalogName
abx831460-01Faricimab
KDA42301Faricimab ELISA Kit
abx392504Human Anti-Faricimab Antibody (Anti-Faricimab) ELISA Kit
DHA42301Research Grade Faricimab
ICH5320-50mgFaricimab Biosimilar - Research Grade
B23150101-01Anti-Human VEGFAxANGPT2 (Faricimab)
E55B1240Faricimab (Reference antibody)
KBI1326KRIBIOLISA™ Faricimab (VABYSMO) ELISA
F2090-.1Anti-ANG2 & VEGFA Antibody (Faricimab)
591856-01ANGPT2 + VEGFA, Faricimab Biosimilar

Popular Products